Tabriz University of Medical Sciences BioImpacts 2228-5652 16 1 2026 01 04 Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies 33219 33219 10.34172/bi.33219 EN Qamar Abuhassan https://orcid.org/0000-0002-1038-6483 Kamel Saleh https://orcid.org/0000-0002-0360-6257 S. Renuka Jyothi Radhamadhab Sahoo P. Prakash Gunjan Mukherjee Aashna Sinha Turabek Boyqulov Journal Article 10.34172/bi.33219 2025 11 25 2026 02 23 Ocular malignancies, particularly uveal and conjunctival melanoma, exemplify tumors that evolve within one of the body’s most immunologically constrained ecosystems, the eye’s immune-privileged microenvironment. The limited success of PD-1/PD-L1 and CTLA-4 blockade in these cancers underscores the need to move beyond linear checkpoint inhibition toward multidimensional immune engineering. Through the confluence of synthetic bio-nanotechnology, AI-guided immunogenomics, and spatial immunomics, this review reframes ocular immunotherapy and redefines how tolerance and immunity might be programmatically regulated within ocular tissue. We synthesize recent advances in bispecific T-cell engagers, oncolytic viro-immunotherapy, mRNA and dendritic-cell vaccines, and engineered CAR/TCR-T platforms, highlighting how they collectively reconfigure the ocular tumor microenvironment from immune-silent to immune-responsive. Logic-gated antibodies, ROS-responsive nanocarriers, and CRISPR-assisted checkpoint reprogramming are added to the notion of "precision immune engineering". These developments are intended to temporarily alter immune privilege without sacrificing visual quality. Lastly, we suggest a systems-level model for ocular immuno-oncology 2.0, where immune privilege is not an unchangeable barrier but rather a configurable circuit for therapeutic orchestration. One element of a dynamic, closed-loop immune-engineering architecture is checkpoint inhibition. This platform offers the possibility of long-lasting, vision-preserving disease treatment by combining AI-driven neoantigen detection, liquid-biopsy feedback loops, and flexible delivery biomaterials. While several of these approaches remain at a conceptual or early translational stage, they outline a plausible roadmap toward vision-preserving immunotherapy in ocular oncology.